SUBCUTANEOUS BORTEZOMIB IN PATIENTS OVER 75 YEARS WITH MULTIPLE MYELOMA

被引：0
作者：
Violeta, Martinez-Robles [1 ]
Belen, Ballina [1 ]
Seila, Cerda [1 ]
Filomeno, Rondon [1 ]
Natalia, De Las Heras [1 ]
Jose-Antonio, Rodriguez-Garcia [1 ]
Fernando, Escalante [1 ]
机构：
[1] Complejo Asistencial Univ Leon, Leon, Spain
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB-003
引用
收藏
页码：302 / 302
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF THREE SUBCUTANEOUS BORTEZOMIB COMBINATIONS IN ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Cerrato, C.
    Oliva, S.
    Petrucci, M. T.
    Caraffa, P.
    Nozzoli, C.
    Finsinger, P.
    Larocca, A.
    De Rosa, L.
    De Paoli, L.
    Montefusco, V.
    Saraci, E.
    Villani, O.
    Carella, A. M.
    Benevolo, G.
    Morabito, F.
    Liberati, A. M.
    Derudas, D.
    Boccadoro, M.
    Sonneveld, P.
    Palumbo, A.
    HAEMATOLOGICA, 2014, 99 : 107 - 107
  • [32] INTRAVENOUS SWITCHING OF BORTEZOMIB CAN OVERCOME RESISTANCE AFTER SUBCUTANEOUS ADMINSTRATION IN MULTIPLE MYELOMA PATIENTS
    Gozzetti, A.
    Candi, V.
    Papini, G.
    Defina, M.
    Schiattone, L.
    Bocchia, M.
    HAEMATOLOGICA, 2014, 99 : 651 - 652
  • [33] Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
    Wu, Shenghao
    Zheng, Cuiping
    Chen, Songyan
    Cai, Xiaoping
    Shi, Yuejian
    Lin, Bijing
    Chen, Yuemiao
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [34] Real world outcomes in multiple myeloma in patients aged 75 and over
    Hopkins, D.
    Holmes, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 116 - 116
  • [35] Subcutaneous bortezomib may be the better delivery method to treat multiple myeloma
    Wraight, Sophie
    EXPERT REVIEW OF HEMATOLOGY, 2012, 5 (06) : 591 - 591
  • [36] At what point are we on the way to optimally treat multiple myeloma patients over 75 years of age in 2023?
    Tyczynska, Agata
    Zaucha, Jan
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 33 (04): : 409 - 418
  • [37] Bortezomib in renally impaired multiple myeloma patients
    Miguel, J. F. San
    Richardson, P. G.
    Sonneveld, P.
    Schuster, M. W.
    Irwin, D.
    Stadtmauer, E. A.
    Facon, T.
    Harousseau, J. L.
    Ben-Yehuda, D.
    Lonial, S.
    Goldschmidt, H.
    Reece, D.
    Blade, J.
    Boccadoro, M.
    Neuwirth, R.
    Boral, A. L.
    Esseltine, D. L.
    Anderson, K. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 214 - 215
  • [38] Community experience with bortezomib in patients with multiple myeloma
    Onitilo, Adedayo A.
    Engel, Jessica
    Olatosi, Bankole
    Fagbemi, Seth
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (07) : 637 - 639
  • [39] SUBCUTANEOUS BORTEZOMIB CONTAINING REGIMENS AS UPFRONT TREATMENT OF NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
    Rizzello, I.
    Zamagni, E.
    Dozza, L.
    Quaresima, M.
    Petrucci, M. T.
    De Stefano, V.
    Antonioli, E.
    Tosi, P.
    D'Agostino, M.
    Offidani, M.
    Gozzetti, A.
    Rivoli, G.
    Testoni, N.
    Martello, M.
    Tacchetti, P.
    Pantani, L.
    Mancuso, K.
    Rocchi, S.
    Caratozzolo, I.
    Cavo, M.
    HAEMATOLOGICA, 2019, 104 : 117 - 117
  • [40] Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis
    Ye, Ziqi
    Chen, Jie
    Xuan, Zixue
    Yang, Wenchao
    Chen, Jing
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 1707 - 1716
12345